MedTrace Logo

Abemaciclib + Pembrolizumab In Glioblastoma

NCT04118036 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-08-11

No results posted yet for this study

Summary

This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

This study will involve participants with recurrent glioblastoma at their first relapse enrolled in two arms including patients who require reoperation and patients not requiring surgery.

This research study involves a combination of two drugs:

* Pembrolizumab (MK3475)
* Abemaciclib (LY2835219)

Conditions

Interventions

DRUG

Pembrolizumab

intravenously over 30 minutes every 21 days (+/- 3 days)

DRUG

Abemaciclib

Oral 2 times a day

Sponsors & Collaborators

Principal Investigators

  • Patrick Wen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-12-01
Completion
2024-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04118036 on ClinicalTrials.gov